Consistent control of mineral and bone disorder in incident hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 5, 2008, Pages 1423-1429

  Danese, Mark D ^a,b   Belozeroff, Vasily ^c   Smirnakis, Karen ^c   Rothman, Kenneth J ^d  

^a Outcomes Insights Inc   (United States)

^b Amgen Inc ^*  (United States)

^c AMGEN INC   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

AGED; ARTICLE; BLOOD; CHRONIC DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; INCIDENCE; KIDNEY DISEASE; MALE; METABOLIC BONE DISEASE; METABOLIC DISORDER; METABOLISM; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; TIME;

AGED; BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; CALCIUM; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; METABOLIC DISEASES; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK ASSESSMENT; TIME FACTORS;

EID: 53749105878     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01060308     Document Type: Article

References (26)

1. Eknoyan G, Levin NW: Impact of the new K/DOQI guidelines. Blood Purif 20: 103-108, 2002
2. Owda A, Elhwairis H, Narra S, Towery H, Osama. S: Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail 25: 595-602, 2003
3. NKF-K/DOQI: Bone Disease and Metabolism Treatment Guidelines, National Kidney Foundation, 2006. Available at http://www.kidney.org/ professionals/KDOQI/guidehnes_bone/index.htm. Accessed December 10, 2007
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
6. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
7. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788-1793, 2005
8. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770-779, 2004
9. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187, 2005
10. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT: The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis 46: 925-932, 2005
11. Al AZ, Gonzalez EA, Martin KJ, Gellens; ME: Achieving K/DOQI laboratory target values for bone and mineral metabolism: An uphill battle. Am J Nephrol 24: 422-426, 2004
12. Arenas MD, varez-Ude F, Gil MT, Soriano A, Egea JJ, Millan I, Amoedo ML, Muray S, Carreton MA: Application of NKF-K/DOQI clinical practice guidelines for bone metabolism and disease: Changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 21: 1663-1668, 2006
13. Maduell F, Gorriz JL, Pallardo LM, Pons R, Santiago C: Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia. J Nephrol 18: 739-748, 2005
14. Arenas MD, Alvarez-Ude F, Torregrosa V, Gill M, Carreton M, Moledous A, Nunez C, Devesa R, Alblach B: Consequences of the implementation of "K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease" in a population of patients on chronic hemodialysis. J Nephrol 20: 453-461, 2007
15. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI bone metabolism and:disease treatment goals with cinacalcet HCl. Kidney Int 67: 760-771, 2005
16. Tentori F, Hunt WC, Rohrscheib M, Zhu M, Stidley CA, Servilla K, Miskulin D, Meyer KB, Bedrick EJ, Johnson HK, Zager PG: Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 18: 2377-2384, 2007
17. Rothman KJ, Greenland S, Lash TL: Modern Epidemiology, 3rd Ed., New York, Lippincott Williams & Wilkins, 2008
18. Greenland S: Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 160: 301-305, 2004
19. Miettinen OS: Stratification by a multivariate confounder score. Am J Epidemiol 104: 609-620, 2007
20. Strauss D: On Miettinen's multivariate confounder score. J Clin Epidemiol 51: 233-236, 1998
21. Therneau. TM, Grambsch PM: Modeling Survival Data, 1st Ed., New York, Springer-Verlag, 2000
22. Avram MM, Mittman N, Myint MM, Fein P: Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38: 1351-1357, 2001
23. Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH: Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 39: 1245-1254, 2002
24. Gallieni M, Brancaccio D, Antonucci F, Bellinghieri G, Carpani P, Cozzolino M, D'Agostino F, Del MG, Mallamace A, Memoli B: Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: A randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale. Clin Nephrol 53: 188-193, 2000
25. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
26. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005